Sean Humphrey receives two prestigious awards for brain cancer research

Dr Sean Humphrey, who manages the reNEW Functional Phosphoproteomics Platform, has been awarded the Peter Doherty Investigator Award, the highest ranked recipient of a research grant in the Emerging Leadership category, by the National Health and Medical Research Council (NMHRC).

Dr Humphrey was also awarded the 2024 Commonwealth Health Minister’s Award for Excellence in Health and Medical Research for his outstanding scientific contributions.

By accepting this prestigious award, Dr Humphrey will receive a further $50,000 to help support his research in addition to his recent 5-year NHMRC Investigator Grant funding.

Dr Humphrey, from reNEW Melbourne and based at the Murdoch Children’s Research Institute, leads the Functional Phosphoproteomics group and focuses on developing new ways to study proteins and how they are modified in the cell by a process called ‘phosphorylation’.

This funding will allow Dr Humphrey and his collaborators to further explore the cells that make up medulloblastoma, the most common type of childhood brain cancer.

Read the full article on the MCRI website:

Esteemed colleagues from reNEW elected members of EMBO

The Novo Nordisk Foundation Center for Stem Cell Medicine is proud to announce that CEO and Executive Director of reNEW, Professor Mellissa H. Little and Principal Investigator at reNEW’s Copenhagen node, Professor Joshua Brickman, have this year been elected members of the prestigious European Molecular Biology Organization – EMBO.

4M euros for research into nuclear metabolism

Associate Professor Jan Żylicz from reNEW Copenhagen node, as part of an international consortium, has been awarded an MSCA Doctoral Networks Grant for project; NUCLEAR – metabolic regulation of genome function and cell identity.

The Serup Group in Copenhagen break new ground on the development of a stem cell therapy to treat diabetes

Assistant Professor Philip Seymour, former Assistant Professor Nina Funa and PhD student Heidi Mjøseng, with colleagues from the Serup Group at the Novo Nordisk Foundation Center for Stem Cell Medicine, reNEW, University of Copenhagen, have had a paper published in Stem Cell Reports investigating further development of a cellular therapy to replace the lost insulin-producing beta cells in type one diabetics.